243 related articles for article (PubMed ID: 16114993)
1. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
2. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
5. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery.
Wiering B; Ruers TJ; Krabbe PF; Dekker HM; Oyen WJ
Ann Surg Oncol; 2007 Feb; 14(2):818-26. PubMed ID: 17136470
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
Strasberg SM; Dehdashti F
J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
[TBL] [Abstract][Full Text] [Related]
9. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
[TBL] [Abstract][Full Text] [Related]
10. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
McLeish AR; Lee ST; Byrne AJ; Scott AM
ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
[TBL] [Abstract][Full Text] [Related]
11. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
[TBL] [Abstract][Full Text] [Related]
12. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
[TBL] [Abstract][Full Text] [Related]
14. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
[TBL] [Abstract][Full Text] [Related]
16. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
19. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.
Zealley IA; Skehan SJ; Rawlinson J; Coates G; Nahmias C; Somers S
Radiographics; 2001 Oct; 21 Spec No():S55-69. PubMed ID: 11598248
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]